Last reviewed · How we verify
Fluarix TM
Fluarix is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against seasonal influenza virus strains.
Fluarix is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against seasonal influenza virus strains. Used for Seasonal influenza prevention in adults and children ≥6 months of age.
At a glance
| Generic name | Fluarix TM |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Inactivated influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Fluarix contains inactivated (killed) influenza virus antigens from three or four seasonal flu strains. When administered, it triggers the adaptive immune response, prompting B cells to produce neutralizing antibodies and T cells to develop cellular immunity against the included influenza strains. This immune priming protects vaccinated individuals from infection or reduces disease severity if exposure occurs.
Approved indications
- Seasonal influenza prevention in adults and children ≥6 months of age
Common side effects
- Injection site soreness, redness, or swelling
- Myalgia (muscle aches)
- Headache
- Fatigue
- Low-grade fever
Key clinical trials
- Spirulina Oral Supplement for Enhancing Host Resilience to Virus Infection (PHASE3)
- Influenza Challenge Study to Determine the Optimal Infection Dose and Safety of a Recombinant H3N2 (A/Texas/71/2017 (H3N2, Clade 3C3a) Influenza Strain (PHASE1)
- Community-based Behavioral Intervention to Increase Vaccination Using MOST (PHASE2)
- Immunogenicity of Alternative Annual Influenza Vaccination Strategies in Older Adults in Hong Kong (PHASE4)
- Phase Ⅲ, Clinical Trial to Compare an Inactivated Quadrivalent Influenza Vaccine and a Licensed Vaccine in Chile (PHASE3)
- Trial to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Year of Age and Older (PHASE3)
- Study to Demonstrate the Lot-to-lot Consistency and to Evaluate the Safety of an Adjuvanted Influenza Vaccine Candidate (PHASE2)
- Study to Evaluate the Immune Response and the Safety of Fluarix TM/ Influsplit SSW® 2010/2011 or Pandemrix TM (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluarix TM CI brief — competitive landscape report
- Fluarix TM updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI